Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.

Richard Adams,David Fisher,Janet Graham,Jenny F. Seligmann,Matthew T. Seymour,Richard Kaplan,Emma Yates,Susan D. Richman,Philip Quirke,Rachel Butler,Ewan Brown,Stephen Falk,Fiona Collinson,Richard H. Wilson,Louise Brown,Tim Maughan,Focus Investigators

Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.

2021

Richard Adams
David Fisher
Janet Graham
Jenny F. Seligmann
Matthew T. Seymour
Richard Kaplan
Emma Yates
Susan D. Richman
Philip Quirke
Rachel Butler
Ewan Brown
Stephen Falk
Fiona Collinson
Richard H. Wilson
Louise Brown
Tim Maughan
Focus Investigators

3504Background: There is extensive randomised evidence supporting the use of treatment breaks in mCRC, but breaks from treatment are not universally offered to patients despite reductions in toxici...

Keywords:

Active monitoring
Medicine
Colorectal cancer
Oncology
first line treatment
Internal medicine
Capecitabine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations